Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | PDE1A | P54750 | 1/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.46 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177656 | 0.99 | PDE4A (0.51) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL3175131 | 0.96 | PDE4A (0.57) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL3175170 | 0.90 | PDE4A (0.55) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL3119443 | 0.89 | SIRT1 (0.54) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL13247926 | 0.87 | ADORA2B (0.53) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL13247927 | 0.87 | ADORA2B (0.53) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL7031457 | 0.87 | SIRT1 (0.55) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL3116013 | 0.86 | ADORA2B (0.47) | ADORA2AADORA2B | |
| SCHEMBL3181178 | 0.85 | ADORA2A (0.54) | PDE4AADORA2APDE4BPDE4CPDE4D | |
| SCHEMBL13247661 | 0.85 | ADORA2B (0.49) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251675-B1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | SHANTON PHARMA PTE LTD (SG) | 2021-04-21 | — | — | EP | claimed |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | SHANTON PHARMA CO., LTD (CN) | 2019-06-18 | — | — | US | claimed |
| EP-3251675-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Co., Ltd. (CN) | 2017-12-06 | — | — | EP | claimed |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Pte. Ltd. (SG) | 2017-11-16 | — | — | US | claimed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | claimed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | claimed |
| EP-1781657-B1 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-03-27 | — | — | EP | claimed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | claimed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | claimed |
| EP-3251675-B1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | SHANTON PHARMA PTE LTD (SG) | 2021-04-21 | — | — | EP | disclosed |
| EP-3251675-B1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | SHANTON PHARMA PTE LTD (SG) | 2021-04-21 | — | — | EP | disclosed |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | SHANTON PHARMA CO., LTD (CN) | 2019-06-18 | — | — | US | disclosed |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | SHANTON PHARMA CO., LTD (CN) | 2019-06-18 | — | — | US | disclosed |
| EP-3251675-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | Shanton Pharma Co., Ltd. (CN) | 2017-12-06 | — | — | EP | disclosed |
| US-20100010021-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED | 2010-01-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| EP-1781657-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2005077950-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135456-A1 | Medicaments with hm74a receptor activity | HCAR1, GPR84, HCAR3 | PDE4A 679/4885ADORA2A 12/4885PDE4B 1199/4885 |
| US-20150080418-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | PDE4A 408/4885ADORA2A 8/4885PDE4B 592/4885 |
| US-20170326148-A1 | PREVENTION OR TREATMENT OF URIC ACID OR GOUT DISEASE | NLRP3, REN, SLC5A1 | PDE4A 3392/4885ADORA2A 2329/4885PDE4B 3496/4885 |
| US-20130150383-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | PDE4A 408/4885ADORA2A 8/4885PDE4B 592/4885 |
| US-10322132-B2 | Prevention or treatment of uratic or gouty diseases | REN, NLRP3, SLC5A1 | PDE4A 3590/4885ADORA2A 2737/4885PDE4B 3708/4885 |
| US-20100010021-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | PDE4A 408/4885ADORA2A 8/4885PDE4B 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.